Report Overview

Indian Adrenoleukodystrophy (ALD) Treatment Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Adrenoleukodystrophy (ALD) is one of the rare genetic disorder which is linked with the X chromosome in males and females. Childhood cerebral ALD are found in children of age 3-10 and which can cause severe disability and even death. Addisons disease can be caused when the adrenal glands are unable to produce sufficient hormones. It is also known as adrenal insufficiency. Adrenoleukodystrophy (ALD) is mostly observed in childhood and present in both males and females. Adrenoleukodystrophy (ALD) is further recognized by its phenotypes such as childhood onset of ALD, Addison disease, adrenoleukodystrophy and diagnosed with the help of blood testing, magnetic resonance imaging, vision screening, skin biopsy and fibroblast cell culture. Treatment which can be used for Adrenoleukodystrophy (ALD) are stem cell transplant, adrenal insufficiency treatment, dietary therapy, gene therapy.



Market Drivers

Rising demand for new treatment and therapies can act as a market driver, beside this the increasing awareness regarding adrenoleukodystrophy and its treatment is also accelerating the market growth. Government support for the research & development for new and better treatment and rising healthcare expenditure is also boosting the market growth.